Intrastromal injection of bevacizumab in patients with corneal neovascularization

Arquivos Brasileiros de Oftalmologia

Ana Carolina Cabreira Vieira¹  Ana Luisa Höfling-lima¹  José Álvaro P. Gomes¹  Denise De Freitas¹  Michel Eid Farah¹  Rubens Belfort Jr.¹ 

[1] ,Universidade Federal de São Paulo Vision Institute Department of OphthalmologySão Paulo SP ,Brazil

关键词: Corneal stroma;    Corneal neovascularization;    Injections;    intraocular;    Antibodies;    monoclonal;    Substância própria;    Neovascularização da córnea;    Injeções intraoculares;    Anticorpos monoclonais;   

DOI  :  10.1590/S0004-27492012000400012

来源: SciELO

【 摘 要 】

Corneal neovascularization (NV) not only reduces visual acuity, but it also causes loss of the cornea's immune privilege, strongly contributing to a worse prognosis in penetrating keratoplasty. Several mediators participate in corneal angiogenesis, and the role of vascular endothelial growth factor (VEGF) has been extensively proven. Anti-VEGF agents have been shown to be effective in slowing the growth of corneal neovessels. Bevacizumab, an anti-VEGF agent, has been successfully used in the treatment of corneal neovascularization. In this paper, we report a series of patients who underwent intracorneal bevacizumab injections to treat corneal vascularization.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License